Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc.

TVRD - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$9.26M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Tvardi Therapeutics, Inc.Tvardi Therapeutics, Inc.-0.4--203%-1-
$2.64

Current Fair Value

166.7% upside

Undervalued by 166.7% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$9.26 Million
Enterprise Value$-12,902,120.00
Earnings per Share$-2.46
Beta0.36
Outstanding Shares9,357,000

Return

Return on Equity-202.72%ROE
Return on Assets-133.14%
Return on Invested Capital-209.37%

Valuation & Multiples

P/E Ratio-0.42P/E Ratio
PEG-3.92PEG
Price to Sales-0.99Price to Sales
Price to Book Ratio0.99Price to Book Ratio
Enterprise Value to Revenue5.47
Enterprise Value to EBIT0.43
Enterprise Value to Net Income0
Total Debt to Enterprise-0.01
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 13, 2026
EPS
-$0.48
Est. -$0.57
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 30, 2027
EPS Estimate
-$0.50
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls34,300▲ Infinity%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %38.55%▲ 14.74%
Total Invested$4.51M▲ 6.33%
Investors Holding57▼ 2.00%

About Cara Therapeutics Inc

12 employees
CEO: Derek Chalmers

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and...

Questions & Answers